With our PartnerYourAntibodies® initiative we are looking for novel antibodies relating particularly to the fields of cardiology (including kidney diseases and acute care), lung diseases, oncology, hemophilia as well as gynecology and addressing a specific target or pathway in a selective manner (functional activity). Successful applications will be assessed by us with regard to bioactivity.
Novel antibodies in Bayer’s current research focus
Areas of interest include cardiology, lung diseases, oncology, hemophilia, gynecology
Bayer offers substantial financial funding for promising proposals
How It Works?
● Non-confidential, and should include information on the antibody properties
(without amino acid sequence)
● Submission will be reviewed by senior scientists at Bayer within 8 weeks
● Selected applicant will be invited to MTA or CDA process, and will receive a reasonable monetary compensation
● Second level assessment under MTA or CDA
If successful, Bayer might propose a collaboration under an antibody exploration program
※ Currently, we are not accepting new submissions. Please stay tuned until new application reopens.